Literature DB >> 16425524

Current issues in lung cancer screening.

James L Mulshine1.   

Abstract

Despite improvements in drug therapy, late-stage lung cancer remains routinely incurable. The field of screening for early lung cancer is a challenging, fast-moving, cross-disciplinary area, not without controversy. The ideal situation is one in which we approach screening proactively to allow it to mature as a public health strategy. Spiral CT screening for lung cancer is a new and promising approach to thoracic imaging; it allows for a much more rapid and comprehensive evaluation of a structure than the original CT scan. In this review we will discuss issues inherent to the lung cancer screening process, including the value of smoking cessation strategies, the challenge with the rapid pace of developments in the field, cost concerns, consideration of biases in trial design (overdiagnosis, for example), overtreatment, and radiation risk. We discuss recommendations from several organizations, such as the US Preventive Services Task Force and the American Cancer Society.

Entities:  

Mesh:

Year:  2005        PMID: 16425524

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  2 in total

1.  Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.

Authors:  Kristin A Spivey; Jacqueline Banyard; Luisa M Solis; Ignacio I Wistuba; Justine A Barletta; Leena Gandhi; Henry A Feldman; Scott J Rodig; Lucian R Chirieac; Bruce R Zetter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05       Impact factor: 4.254

2.  Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease.

Authors:  Michael K Showe; Anil Vachani; Andrew V Kossenkov; Malik Yousef; Calen Nichols; Elena V Nikonova; Celia Chang; John Kucharczuk; Bao Tran; Elliot Wakeam; Ting An Yie; David Speicher; William N Rom; Steven Albelda; Louise C Showe
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.